Extended Release Pellets
DEVELOPMENT OF A NOVEL ENTERIC COATED EXTENDED RELEASE PELLETS USING MODEL NSAID FLURBIPROFEN
... coated extended release pellets was successfully developed by coating the Flurbiprofen core pellets with Eudragit L100-55 and Eudragit RS30D which produces a 2 hr lag time in acidic medium ...
7
FORMULATION DEVELOPMENT OF VENLAFAXINE HYDROCHLORIDE EXTENDED RELEASE PELLETS BY EXTRUSION SPHERONIZATION METHOD
... prepare extended release pellets of Venlafaxine ...work, extended release pellets of Venlafaxine was prepared by extrusion spheronization method using combination of hydrophobic ...
8
“Design and Development of Extended Release Pellets Delivery of Desvenlafaxine by Employing Principles of Quality by Design” by Dharmesh B. Patel, Girish K. Jani, India.
... formulate extended release pellets of DV. The pellets were prepared by extrusion spheronization technique and appropriate extended release coating was applied by fluidized bed ...
9
FORMULATION AND EVALUATION OF EXTENDED RELEASE PELLETS OF PIOGLITAZONE HYDROCHLORIDE USING NATURAL AND SYNTHETIC POLYMERS BY FLUIDIZED BED COATING TECHNIQUE
... drug release for a prolonged period of time as ...size. Extended-release pellets of Pioglitazone HCL were formulated and evaluated, Eudragit L-100 is used as a synthetic polymer to retard the ...
9
Process Optimization of Methylphenidate Hydrochloride Extended Release Pellets by QbD
... The independent variables in drug layering process were product temperature, atomization air pressure, and flu- idization air volume and spray rate. These process variables were studied at three levels (-1, 0, +1), the ...
11
Quality by Design (Qbd) Assisted Development of Extended Release Pellets of Venlafaxine HCL
... VEN pellets. FMEA analysis riddled two significant factors (% Extended release coat and % EC) affecting quality of VEN ...developed pellets was witnessed by SEM ...into extended ...
9
Formulation and Evaluation of Indomethacin Extended Release Pellets.
... The site-specific delivery of drugs to the colon has implications in a number of therapeutic areas, which include topical treatment of colonic disorders such as Crohn’s disease, ulcerative colitis, constipation, ...
111
Formulation and Evaluation of Metoprolol Succinate Extended Release Pellets.
... Ajay L. et al., (2010) this work aims at investigating different types and levels of hydrophilic matrixing agents, including sodium alginate (Alg), and Hydroxypropyl methyl cellulose K15M (HPMC K15M) in an attempt to ...
128
FORMULATION AND DEVELOPMENT OF FLAVOXATE HYDROCHLORIDE EXTENDED RELEASE CAPSULES
... CONCLUSION: Extended release pellets of Flavoxate hydrochloride were successfully prepared by extrusion spheronization ...the release of the drug. The coated pellets were found to be ...
8
Lipids bearing extruded-spheronized pellets for extended release of poorly soluble antiemetic agent—Meclizine HCl
... system, pellets provide added benefits of multiple unit dosage ...of pellets reduce peak plasma fluctuations and minimize risk of dose ...that pellets provide flexibility in doses by variations in ...
16
PREPARATION AND EVALUATION OF SUSTAINED RELEASE PELLETS OF SAXAGLIPTIN BY EXTRUSION SPHERONIZATION
... unit pellets where a coating of the drug with sugar sphere and further coatings gives the sealing of the drug and to obtain sustain release dosage form, by the process palletization ...[2-3] Pellets ...
14
Formulation and in vitro evaluation of bosentan osmatic controlled release tablets
... Modified Release system is that: “The drug release characteristics of time, course and/or location are chosen to accomplish therapeutic or convenience objectives not offered by conventional dosage ...
9
The influence of formulation on the formation of and drug release from film coated pellets
... Actually pellets prepared with calcium phosphate as well as with barium sulphate (however to a lesser extent) repeatedly showed small pieces of the coat membrane floating in the dissolution vessel after 5 to 6 ...
304
FORMULATION AND EVALUATION OF DOMPERIDONE SUSTAINED RELEASE PELLETS USING DIFFERENT POLYMERS AND DIFFERENT TECHNIQUES
... formulations. Pellets of the formulation F-8 passed all official and unofficial quality control ...vitro release profiles of optimized formulations of Domperidone tablets (F-8), was found to be similar to ...
12
FORMULATION AND EVALUATION OF DELAYED RELEASE ESOMEPRAZOLE PELLETS BY SUSPENSION LAYERING OF PELLETIZATION TECHNIQUE
... The most classified pelletization process involves three consecutive regions nucleation, coalescence and layering, abrasion transfer. Nucleation (Figure 3, A) occurs whenever a powder is wetted with liquid and presents ...
14
FORMULATION AND CHARACTERISATION OF SUSTAINED RELEASE CARVEDILOL TABLET FROM RESERVOIR PELLETS
... Sustained release Carvedilol tablets constituting reservoir pellets developed in this study is an attempt to investigate the effect of drug release from ...sustained release Carvedilol tablets ...
9
“ONCE DAILY VENLAFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS: COMPARISON BETWEEN MATRIX TABLET AND PELLETS” by Sritharan Seetharaman, Narayanan Nallaperumal, India.
... to pellets based on pelletization ...depressant. Extended release tablets of Venlafaxine hydrochloride to be taken once daily were formulated with Venlafaxine hydrochloride equivalent to 150 mg of ...
5
“Controlled Release Orally Disintegrating Tablets: A Review” by Harsha Kathpalia, Bhairavi Sule, India.
... This technology of Aptalis facilitates the development of controlled-release delivery systems for once- or twice- daily dosing of single drug or drug combinations that exhibit extreme pH-dependent solubility ...
8
FORMULATION AND EVALUATION OF PELLETS LOADED WITH DILTIAZEM HYDROCHLORIDE FOR SUSTAINED RELEASE
... an extended period of time in the ...sustained release and controlled release properties in a delivery system would further enhance therapeutic ...
16
Formulation and evaluation of immediate release pellets containing artemether and lumefantrine
... . Pellets have many advantages they Disperse freely in the GI& invariably maximize drug absorption, Reduce peak plasma fluctuation, Minimize potential side effects without lowering bioavailability Avoiding ...
11